format
antibodi
interferonbeta
ifnb
proteinbas
diseasemodifi
agent
multipl
sclerosi
ms
problem
clinic
practic
antibodi
may
neutral
biolog
effect
protein
drug
potenti
decreas
therapeut
effect
highresolut
hla
class
ii
type
identifi
two
hla
class
ii
allel
associ
develop
antibodi
ifnb
two
independ
continu
binarytrait
associ
studi
odd
ratio
hla
alleleswer
strongli
associ
develop
bind
neutral
antibodi
ifnb
associ
allel
differ
nonassoci
allel
glycinetovalin
substitut
posit
epitopebind
alphahelix
hla
class
ii
molecul
peptidebind
motif
might
promot
bind
present
immunogen
peptid
may
eventu
break
tcell
toler
facilit
antibodi
develop
ifnb
summari
identifi
genet
factor
determin
immunogen
ifnb
proteinbas
diseasemodifi
agent
treatment
ms
multipl
sclerosi
ms
mim
chronic
inflammatori
diseas
central
nervou
system
wherea
etiolog
ms
like
heterogen
influenc
genet
factor
develop
ms
confirm
associ
linkag
studi
crucial
role
hla
allel
suscept
ms
well
establish
wherea
allel
strongli
associ
ms
european
overrepres
ms
patient
southern
europ
overrepresent
allel
report
patient
turkey
canari
island
although
genet
associ
suscept
ms
loci
outsid
hla
complex
confirm
case
search
suscept
gene
continu
interferonb
wide
use
immunomodulatori
drug
ms
therapi
approv
treatment
clinic
isol
syndrom
relapsingremit
ms
furthermor
antivir
activ
remain
option
therapi
diseas
hepatitisc
hcv
mim
sever
acut
respiratori
syndrom
sar
like
proteinbas
diseasemodifi
agent
ifnb
exhibit
immunogen
even
though
technic
improv
purif
process
introduct
recombin
prepar
help
reduc
immunogen
ifnb
patient
may
develop
antibodi
ifnb
bind
antibodi
bab
signific
proport
neutral
activ
ifnb
neutral
antibodi
nab
vitro
vivo
current
three
distinct
recombin
prepar
ifnb
use
treatment
ms
interferon
residu
modifi
natur
occur
ifnb
delet
lead
methionin
singl
amino
acid
substitut
recombinantli
express
escherichia
coli
betaferon
betaseron
recombinantli
express
chines
hamster
ovari
cell
ident
natur
human
interferon
beta
residu
avonex
rebif
although
prepar
administr
influenc
immunogen
properti
rate
antibodi
develop
littl
known
host
factor
determin
immun
respons
ifnb
antibodi
product
gener
b
cell
respons
protein
depend
help
antigenspecif
cell
develop
antigenspecif
cell
respons
strongli
influenc
individu
repertoir
hla
class
ii
molecul
present
peptid
antigen
recognit
cell
receptor
given
central
role
cell
develop
antigenspecif
b
cell
respons
perform
highresolut
type
hlaa
b
c
allel
ms
patient
receiv
longterm
ifnb
therapi
patient
ms
patient
ifnb
therapi
predominantli
northern
european
heritag
recruit
germani
primarycar
physician
neurologist
initi
studi
group
includ
individu
known
statu
ratio
male
femal
first
cohort
total
patient
receiv
intramuscular
inject
im
weekli
avonex
patient
subcutan
inject
sc
everi
second
day
betaferon
patient
mg
patient
mg
sc
three
time
week
rebif
valid
group
compass
patient
malefemal
ratio
avonex
treatment
administ
patient
rebif
given
individu
patient
receiv
betaferon
expect
im
avonex
treat
patient
underrepres
studi
result
lower
frequenc
antibodi
develop
group
compar
patient
treat
formul
sc
applic
mean
age
yr
first
yr
second
group
tabl
averag
treatment
durat
month
first
month
second
group
durat
drug
exposur
differ
significantli
among
treatment
group
patient
gave
written
inform
consent
studi
approv
ethic
committe
univers
munich
first
studi
cohort
hla
genotyp
hlaa
b
c
perform
hybrid
sequencespecif
oligonucleotid
probe
immobil
microspher
amplifi
genom
dna
sampl
follow
flow
fluorescenceintens
analysi
accord
instruct
manufactur
one
lambda
canoga
park
ca
usa
valid
studi
cohort
hla
analysi
restrict
presenc
absenc
determin
sequencespecif
primer
polymeras
chain
reaction
pcrssp
use
nest
approach
previous
describ
studi
cohort
identif
allel
accomplish
groupspecif
sequenc
exon
sampl
accord
manufactur
instruct
protran
ketschau
germani
detect
antibodi
ifnb
perform
standard
captur
elisa
describ
defin
posit
neg
serum
sampl
includ
assay
obtain
standard
curv
comparison
differ
assay
standard
curv
rang
highest
posit
control
antibodi
serum
posit
test
sampl
normal
basi
standard
curv
reactiv
highest
posit
control
consid
antibodi
posit
cutoff
valu
correspond
median
control
donor
five
standard
deviat
biolog
vivo
activ
ifnb
measur
mxa
gene
express
taqman
realtim
pcr
twelv
hour
ifnb
inject
blood
sampl
drawn
subject
mrna
isol
accord
manufactur
instruct
taqman
reversetranscript
reagent
appli
biosystem
foster
citi
usa
use
convert
mrna
cdna
cdna
level
detect
abi
geneamp
via
protocol
describ
housekeep
gene
gapdh
use
intern
control
normal
done
accord
ddctmethod
assay
posit
neg
sampl
includ
ensur
qualiti
assay
antibodi
consid
biolog
activ
mxa
induct
decreas
compar
newli
treat
antibodyneg
control
donor
patient
first
patient
group
rna
nab
assay
also
perform
determin
vitro
neutral
antibodi
activ
human
lung
carcinoma
cell
line
american
type
cultur
collect
dilut
cultur
group
compris
total
ifnbtreat
subject
mean
treatment
durat
exce
month
cohort
rang
given
bracket
wherea
mean
age
group
yr
sex
ratio
differ
among
group
femal
slightli
overrepres
valid
group
note
number
babsposit
subject
higher
betaferon
treat
group
medium
bc
mm
lglutamin
uml
penicillin
g
mgml
streptomycin
sulfat
alphamem
concentr
cellsml
well
microtit
plate
incub
overnight
ml
solut
screen
sampl
dilut
incub
betaferon
iuml
min
c
microtit
plate
sampl
transfer
plate
contain
cell
incub
hr
standard
curv
betaferon
concentr
iu
use
supernat
decant
cell
lyse
lysi
buffer
dct
valu
sampl
less
highest
concentr
standard
curv
consid
nab
neg
otherwis
sampl
titrat
titrat
sampl
dilut
serial
begin
dilut
incub
betaferon
iuml
min
c
extra
microtit
plate
sampl
transfer
plate
contain
cell
incub
hr
supertnat
decant
cell
lyse
lysi
buffer
follow
rna
extract
transcript
describ
rna
isol
semiautomat
abi
prism
nucleic
prep
station
lysat
filter
membran
captur
rna
sever
wash
step
wash
buffer
appli
biosystem
rna
elut
addit
purif
elut
solut
extract
plate
store
c
master
mix
prepar
highcapac
cdna
kit
appli
biosystem
appli
new
microtit
plate
sampl
rna
plate
thaw
transfer
rna
transcrib
cdna
accord
manufactur
instruct
endogen
control
housekeep
gene
targetdetect
primer
mix
appropri
master
mix
appli
biosystem
cdna
ad
predefin
program
appli
biosystem
hous
keep
gene
eukaryot
rrna
detect
appli
threshold
set
exponenti
phase
rtpcr
differ
threshold
cycl
housekeep
gene
cycl
determin
dct
order
attenu
problem
deliber
set
threshold
elisa
valu
declar
case
control
binarytrait
casecontrol
associ
studi
support
continu
trait
analysi
singl
hla
allel
haplotyp
bilater
approach
use
initi
studi
group
well
valid
group
identif
genet
variat
antiifnb
format
continu
normal
antibodi
reactiv
directli
compar
among
carrier
differ
allel
binarytrait
casecontrol
studi
patient
consid
antibodi
posit
case
antiifnb
level
exceed
cutoff
valu
otherwis
patient
consid
antibodi
neg
control
addit
antibodyposit
patient
consid
nab
posit
mrna
reduc
level
newli
treat
patient
remain
antibodyposit
patient
significantli
reduc
mrna
level
consid
bab
posit
test
differ
locat
paramet
gene
express
antiifnb
level
twosid
nonparametr
wilcoxon
test
appli
p
valu
adjust
multipl
test
falsediscoveri
rate
fdr
identif
haplotypespecif
associ
continu
antiifnb
level
binomi
trait
type
nab
bab
control
subgroup
genet
analysi
packag
gap
r
project
statist
comput
appli
score
test
associ
describ
haplotypespecif
score
calcul
score
test
ambigu
haplotyp
score
statist
given
denot
measur
trait
mean
trait
valu
measur
variat
e
p
gi
denot
expect
valu
posterior
distribut
null
hypothesi
score
statist
provid
measur
covari
haplotyp
examin
trait
howev
analysi
explor
charact
result
base
maxim
probabl
rather
known
linkag
phase
multipl
sequenc
align
gener
clustalw
applic
sequenc
hla
allel
obtain
hla
repositori
european
bioinformat
institut
ebi
linkag
disequilibrium
ld
test
hla
allel
well
multilocu
analysi
ld
done
pypop
packag
hla
class
ii
hla
class
allel
associ
antibodi
occurr
two
hundr
sixtyeight
ms
patient
longterm
ifnb
therapi
includ
first
group
studi
one
hundr
thirtysix
patient
studi
group
develop
antibodi
ifnb
determin
celisa
develop
neutral
antibodi
determin
vivo
induct
ifnb
respons
gene
one
hundr
thirtytwo
patient
antibodi
neg
tabl
second
group
patient
antibodi
posit
includ
neutral
vivo
activ
remain
individu
antibodi
neg
analysi
possibl
confound
effect
treatmentindepend
allel
distribut
test
null
hypothesi
independ
hold
studi
chisquar
p
valu
well
valid
group
chisquar
p
valu
patient
initi
studi
group
type
hla
class
ii
allel
although
expect
associ
hla
class
ii
gene
antibodi
develop
also
type
class
gene
intern
neg
control
expect
small
differ
antibodyneg
posit
patient
found
hla
class
allel
median
antiifnb
level
lower
hlac
carrier
p
valu
fdr
higher
hlac
hlab
p
valu
fdr
carrier
although
associ
reach
signific
adjust
multipl
test
contrast
signific
differ
observ
hla
class
ii
allel
largest
differ
median
antiifnb
level
observ
n
subject
n
p
patient
show
significantli
higher
antiifnb
level
median
normal
antibodi
titer
compar
patient
median
tabl
significantli
reduc
median
antiifnb
reactiv
also
found
p
valu
p
valu
howev
null
hypothesi
kept
fdr
procedur
likewis
elev
antiifnb
reactiv
patient
p
valu
signific
correct
allel
confer
higher
risk
develop
antibodi
ifnb
therapi
major
patient
includ
initi
studi
group
carri
allel
n
wherea
subject
four
patient
carri
tabl
differ
locat
paramet
fdr
fdr
signific
correct
multipl
test
hand
averag
celisa
level
lower
compar
patient
fdr
correct
null
hypothesi
kept
despit
signific
singl
test
p
valu
fdr
investig
role
allel
antibodi
develop
determin
activ
ifnb
antibodi
anoth
assay
use
number
clinic
studi
vitro
test
perform
randomli
select
sampl
expect
signific
increas
p
valu
neutral
vitro
activ
found
sera
subject
median
activ
nu
compar
sera
patient
median
activ
data
shown
valid
initi
find
use
second
studi
cohort
analyz
signific
result
hla
genotyp
valid
group
support
previou
find
fiftynin
individu
posit
carrier
show
significantli
higher
level
antiifnb
antibodi
median
celisa
posit
p
valu
fdr
tabl
five
subject
carri
allel
median
level
wherea
elev
elisa
reactiv
signific
singl
test
null
hypothesi
kept
correct
multipl
test
p
valu
fdr
combin
analysi
antiifnb
level
carrier
valid
studi
group
highli
signific
elev
antiifnb
level
found
carrier
allel
median
reactiv
p
valu
figur
fiftyfour
carrier
show
antibodi
ifnb
treatment
subject
show
seroconvers
result
odd
ratio
carrier
odd
ratio
four
five
allel
carrier
antibodi
posit
highli
signific
increas
elisa
reactiv
observ
comparison
carrier
versu
carrier
figur
p
valu
furthermor
differ
antiifnb
level
among
median
reactiv
median
reactiv
signific
p
valu
small
number
homozyg
carrier
comparison
heterozyg
carrier
possibl
haplotyp
analysi
perform
score
statist
ambigu
haplotyp
drb
allel
might
protect
influenc
haplotyp
analysi
show
signific
reduct
antiifnb
level
drb
carrier
elev
mrna
level
carrier
haplotyp
support
observ
signific
increas
antiifnb
reactiv
could
observ
haplotyp
reduct
mrna
level
howev
signific
p
valu
r
reduc
level
well
increas
antibodi
reactiv
significantli
chang
patient
carri
haplotyp
suscept
seroconvers
increas
carrier
carrier
also
show
significantli
decreas
level
tabl
expect
pairwis
linkag
disequilibrium
signific
observ
major
histocompat
complex
mhc
loci
p
valu
strongest
disequilibria
tabl
avail
onlin
indic
common
transmiss
data
shown
wherea
significantli
associ
presenc
antibodi
frequenc
differ
patient
develop
nab
bab
p
valu
tabl
suggest
antibodi
develop
neutral
capac
influenc
hla
allel
reject
altern
hypothesi
might
howev
caus
insuffici
power
test
odd
ratio
studi
valid
group
develop
antibodi
ifnb
patient
patient
odd
ratio
increas
ifnb
prepar
although
reach
signific
ifnba
imtreat
ifnba
mg
sctreat
patient
result
low
number
patient
treatment
group
odd
ratio
respect
strongest
effect
observ
patient
receiv
sc
treatment
tabl
signific
elev
ifnb
reactiv
seen
bold
adjust
multipl
test
allel
occur
twice
shown
contrast
find
lowresolut
analysi
signific
increas
antiifnb
level
subject
vanish
fdr
procedur
likewis
potenti
protect
effect
pass
signific
criterion
adjust
multipl
test
valid
group
signific
elev
ifnb
reactiv
seen
singl
test
drb
bold
well
insuffici
number
case
howev
signific
vanish
correct
multipl
test
small
number
case
potenti
protect
effect
pass
fdr
signific
criterion
result
valid
group
support
previou
find
allel
list
note
heterozyg
allel
carrier
occur
twice
homozygot
allel
carrier
occur
allel
occur
twice
shown
b
heterozyg
allel
carrier
occur
twice
c
antiifn
reactiv
determin
describ
materi
method
valu
identifi
patient
antiifn
antibodi
p
valu
determin
comparison
antiifn
level
allel
carrier
nonallel
carrier
e
p
valu
adjust
multipl
test
use
falsediscoveri
rate
method
fdr
adjust
p
valu
consid
statist
signific
bold
investig
molecular
basi
hla
class
iirestrict
antibodi
develop
compar
sequenc
antibodyassoci
allel
associ
antibodi
develop
differ
one
amino
acid
kr
differ
posit
form
first
pocket
peptidebind
groov
locat
termin
end
alphahelix
figur
allel
associ
antibodi
develop
share
glycin
posit
wherea
nonassoci
allel
valin
posit
gv
decemb
new
biopharmaceut
approv
us
european
union
japan
sinc
like
ifnb
new
biopharmaceut
deriv
recombin
dna
technolog
applic
rang
treatment
preval
rheumat
diseas
ethanercept
rare
acquir
inherit
diseas
protein
defici
galsulfas
predict
mani
therapeut
protein
becom
avail
near
futur
even
wider
rang
indic
despit
therapeut
potenti
immunogen
common
problem
proteinbas
biopharmaceut
import
aspect
safeti
antibodi
might
lead
loss
drug
efficaci
may
also
induc
sever
allerg
reaction
neutral
activ
endogen
produc
protein
argu
absenc
resili
predictor
immunogen
patient
might
put
high
risk
prepar
handl
packag
dose
frequenc
rout
administr
treatment
durat
seem
affect
immunogen
biopharmaceut
howev
role
genet
factor
immunogen
proteinbas
therapeut
address
present
studi
show
thatbesid
influenc
differ
prepar
immunogenicitygenet
factor
play
import
role
develop
antibodi
protein
therapeut
patient
carri
allel
show
increas
risk
develop
antibodi
ifnb
respect
result
averag
rel
risk
drb
drb
patient
although
allel
increas
risk
develop
antibodi
respons
ifnb
formul
remain
determin
studi
differ
studi
design
whether
formul
higher
immunogen
affect
hla
haplotyp
low
immunogen
result
line
central
role
cell
elicit
b
cell
respons
protein
target
seem
peptidebind
motif
allel
allow
process
bind
ifnb
peptid
break
toler
promot
strong
helper
cell
respons
ifnb
protein
breakdown
toler
promot
b
cell
respons
eventu
lead
develop
antibodi
product
ifnb
protein
strike
effect
critic
depend
singl
amino
acid
allel
sequenc
gv
substitut
allel
like
interfer
elev
immunogen
either
alter
bind
affin
ifnb
peptid
secondari
structur
chang
epitopebind
alpha
helix
affect
present
ifnb
peptid
seem
two
allel
influenc
gener
likelihood
develop
antibodi
respons
independ
ifnb
prepar
although
antibodi
develop
strongli
affect
allel
neutral
activ
antibodi
significantli
influenc
hla
allel
suggest
allel
increas
likelihood
break
toler
protein
antibodi
product
factor
howev
might
determin
whether
antibodi
neutral
ifnb
one
factor
could
intens
immun
respons
ifnb
howev
reject
altern
hypothesi
develop
neutral
antibodi
determin
allel
might
due
insuffici
test
power
remain
clarifi
studi
interestingli
associ
develop
autoantibodi
insulin
congia
et
al
identifi
immunodomin
epitop
transgen
mice
would
proteolyt
destroy
normal
condit
addit
epitop
process
present
human
epsteinbarr
virustransform
b
cell
first
report
influenc
serotyp
develop
porcin
insulin
antibodi
date
back
earli
smaller
glycin
might
endors
bind
epitop
contain
larger
amino
acid
vicin
substitut
site
promot
bind
slight
modif
secondari
structur
although
similar
carri
glycin
posit
analog
diseasemodifi
properti
ms
influenc
antibodi
develop
ifnb
although
signific
singleallel
test
explor
haplotyp
analysi
base
score
test
unkown
linkag
phase
reveal
signific
reduct
product
carrier
addit
haplotyp
analysi
show
signific
increas
antiifnb
reactiv
reduc
mrna
express
carrier
point
allel
might
associ
develop
bind
neutral
antibodi
especi
true
allel
also
potenti
increas
risk
develop
antibodi
ifnb
hand
allel
seem
protect
effect
respect
antibodi
product
recent
shown
tran
interact
allel
play
signific
role
suscept
ms
tran
interact
might
also
play
role
immunogen
biotherapeut
henc
studi
suggest
genet
studi
undertaken
clarifi
influenc
hereditari
factor
immunogen
biotherapeut
improv
treatment
decis
supplement
data
includ
one
tabl
found
articl
onlin
http
wwwajhgorg
